Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 8/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CASR | P41180 | 2/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23449290 | 0.89 | PIK3C3 (0.47) | CETPPIK3C3CASR | |
| SCHEMBL19275742 | 0.81 | PIK3C3 (0.46) | CETPPIK3C3HCRTR1HCRTR2DRD2 | |
| SCHEMBL21725646 | 0.80 | RIPK1 (0.50) | PIK3C3DRD2DRD3 | |
| SCHEMBL19275756 | 0.80 | CHRNB2 (0.55) | PIK3C3 | |
| SCHEMBL22871227 | 0.77 | CHRNB2 (0.53) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL24775502 | 0.73 | DRD2 (0.50) | DRD2 | |
| SCHEMBL24757139 | 0.73 | CHRNB2 (0.47) | DRD2DRD3DRD1DRD4DRD5 | |
| SCHEMBL23449291 | 0.71 | CHRM2 (0.50) | PIK3C3DRD2DRD3 | |
| SCHEMBL22984288 | 0.70 | DRD2 (0.47) | CETPHCRTR2DRD2DRD3 | |
| SCHEMBL30228466 | 0.70 | DRD2 (0.56) | HCRTR2DRD2DRD3DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-11-23 | — | — | US | disclosed |
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210161906-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | CDK6, IL6, CDK4 | CETP 4792/4885PIK3C3 4621/4885HCRTR1 2553/4885 |
| US-11179399-B2 | 6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes | CDK6, IL6, CDK4 | CETP 4792/4885PIK3C3 4621/4885HCRTR1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.